Gentherm Inc — Form 8-K
Filed July 23, 2026 · analyzed by the 8-K Agent
8-K
▲ Likely positive
significance 42/100
What the filing says
Gentherm reported Q2 2026 product revenues of $416.2M (up 11.0% YoY, 9.5% ex-FX), with automotive climate/comfort solutions up 14.1% YoY. The company raised full-year 2026 guidance: product revenues to $1.55B–$1.65B (from $1.5B–$1.6B), adjusted EBITDA to $185M–$200M (from $175M–$195M). Board authorized new $400M stock repurchase program effective July 27, 2026 (replacing prior $110M remaining authorization). Gentherm acquired Innovative Medical Equipment (ThermaZone thermal therapy device) and remains on track to close the Modine Performance Technologies combination in early Q4 2026.
Why this rating
Strong organic growth and guidance raise offset by execution risk on pending Modine deal; modest relative to $854B market cap.
See more from July 23, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.